Table Of Contents

1. Introduction 32
1.1. Objectives Of The Study 32
1.2. Market Definition 32
1.3. Overview Of Europe Topical Corticosteroids Market 32
1.4. Currency And Pricing 33
1.5. Limitation 33
1.6. Markets Covered 34
2. Market Segmentation 38
2.1. Markets Covered 38
2.2. Geographic Scope 40
2.3. Years Considered For The Study 41
2.4. Currency And Pricing 41
2.5. Research Methodology 42
2.6. Primary Interviews With Key Opinion Leaders 46
2.7. Secondary Sources 47
2.8. Assumptions 47
3. Market Overview 48
3.1. Drivers 49
3.1.1. Increasing Prevalence Of Chronic Disease Or Condition 49
3.1.2. Growing Number Of Geriatric Population 49
3.1.3. Growth In Demand Of Topical Drug Delivery Drugs 49
3.1.4. Increasing Investment In Research And Development 50
3.1.5. New Product Launchesby Key Players 50
?
3.2. Restraints 50
3.2.1. Expiry Of Patent For Drugs 50
3.2.2. Weak Reimbursement Policies 50
3.2.3. Stringent Regulatory Policies 51
3.3. Opportunities 51
3.3.1. High Investments In R&D To Innovate New Products 51
3.3.2. Lucrative Opportunities In Emerging Market 51
3.3.3. Increasing Mergers And Acquisitions 51
3.4. Challenges 52
3.4.1. Pricing Pressure By Government 52
3.4.2. Side Effectsof Topical Corticosteroids 53
4. Executive Summary 54
5. Premium Insights 56
6. Europe Topical Corticosteroids Market, By Molecule Name 59
6.1. Overview 60
6.2. Fludroxycortide 62
6.3. Triamcinolone Acetonide 63
6.4. Fluocinolone Acetonide 64
6.5. Antiseptics 65
6.6. Betamethasone 66
6.7. Clobetasone Propionate 67
6.8. Clobetasone Butyrate 68
6.9. Halobetasone 69
6.10. Mometasone 70
6.11. Others 71
?
7. Europe Topical Corticosteroids Market, By Potency Class 72
7.1. Overview 73
7.2. Ultra High 75
7.2.1. Clobetasol Propionate 76
7.2.2. Diflorasone Diacetate 76
7.2.3. Betamethasone Dipropionate Glycol 76
7.3. High 77
7.3.1. Amcinonide 78
7.3.2. Betamethasone Dipropionate 78
7.3.3. Desoximetasone 78
7.3.4. Fluocinonide 78
7.3.5. Others 79
7.4. Moderate 79
7.4.1. Desoximetasone 80
7.4.2. Fluocinolone Acetonide 80
7.4.3. Fludroxycortide 81
7.4.4. Hydrocortisone Valerate 81
7.4.5. Triamcinolone Acetonide 81
7.4.6. Clobetasone Butyrate 81
7.4.7. Others 81
7.5. Mild 82
7.5.1. Hydrocortisone 83
7.5.2. Hydrocortisone Acetate 83
7.5.3. Betamethasone Valerate 83
7.5.4. Desonide 84
7.5.5. Fluocinolone Acetonide 84
7.5.6. Others 84
?
8. Europe Topical Corticosteroids Market, By Application 85
8.1. Overview 86
8.2. Acne 88
8.3. Dermatitis 89
8.4. Psoriasis 89
8.5. Skin Infection 91
8.6. Hyperpigmentation 92
8.7. Melasma 93
8.8. Others 94
9. Europe Topical Corticosteroids Market, By Medication Type 95
9.1. Overview 96
9.2. Ointments 98
9.3. Creams 99
9.4. Liquid & Solutions 100
9.5. Lotions 101
9.6. Gel 102
9.7. Oils 103
9.8. Pastes 104
9.9. Sprays 105
9.10. Others 106
10. Europe Topical Corticosteroids Market, By End-User 107
10.1. Overview 108
10.2. Hospital 110
10.3. Dermatology Clinics 111
10.4. Homecare 112
10.5. Others 113
?
11. Europe Topical Corticosteroids Market,
By Distribution Channel 114
11.1. Overview 115
11.2. Hospital Pharmacies 117
11.3. Pharmacy Stores 118
11.4. Online Pharmacies 119
11.5. Others 120
12. Europe Topical Corticosteroids Market, By Purchase Mode 121
12.1. Overview 122
12.2. Over The Counter (Otc) Based 124
12.3. Prescription Based 125
13. Europe Topical Corticosteroids Market, By Brands 126
13.1. Overview 127
13.2. Betnovate 127
13.3. Betnovate N 127
13.4. Panderm Plus 128
13.5. Lobate 128
13.6. Cosvate G 128
13.7. Clop G 128
13.8. Tenovate Gn 128
13.9. Lobate Gm 128
13.10. Ultiderm 128
13.11. Flutivate 129
13.12. Fexin 129
13.13. Momate 129
13.14. Candiderm 129
13.15. Others 129
?
14. Europe Topical Corticosteroids Market, By Geography 130
14.1. Overview 131
14.2. Europe 167
14.2.1. Germany 179
14.2.2. France 184
14.2.3. U.K. 189
14.2.4. Italy 194
14.2.5. Spain 199
14.2.6. Russia 204
14.2.7. Turkey 209
14.2.8. Belgium 214
14.2.9. Netherlands 219
14.2.10. Switzerland 224
14.2.11. Rest Of Europe 229
15. Europe Topical Corticosteroids Market, Company Landscape 331
15.1. Company Share Analysis; Europe 331
16. Company Profiles 335
16.1. Glaxosmithkline Plc. 335
16.1.1. Company Overview 335
16.1.2. Glaxosmithkline Plc; Revenue Analysis 335
16.1.3. Product Portfolio 336
16.1.4. Recent Developments 336
16.2. Merck & Co. Inc. 337
16.2.1. Company Overview 337
16.2.2. Merck & Co. Inc.; Revenue Analysis 337
16.2.3. Product Portfolio 338
16.2.4. Recent Developments 338
?
16.3. Leo Pharma 339
16.3.1. Company Overview 339
16.3.2. Leo Pharma; Revenue Analysis 339
16.3.3. Product Portfolio 340
16.3.4. Recent Developments 340
16.4. Almirall S.A. 341
16.4.1. Company Overview 341
16.4.2. Almirall S.A.; Company Snapshot 341
16.4.3. Product Portfolio 342
16.4.4. Recent Developments 342
16.5. Valeant Pharmaceuticals International 343
16.5.1. Company Overview 343
16.5.2. Valeant Pharmaceuticals International; Revenue Analysis 343
16.5.3. Product Portfolio 344
16.5.4. Recent Developments 344
16.6. Zylera Pharmaceuticals 345
16.6.1. Company Overview 345
16.6.2. Zylera Pharmaceuticals; Company Snapshot 345
16.6.3. Product Portfolio 346
16.6.4. Recent Developments 346
16.7. Sandoz International Gmbh 347
16.7.1. Company Overview 347
16.7.2. Sandoz International Gmbh; Revenue Analysis 347
16.7.3. Product Portfolio 348
16.7.4. Recent Developments 348
16.8. Pfizer Inc. 349
16.8.1. Company Overview 349
16.8.2. Pfizer Inc.; Revenue Analysis 349
16.8.3. Product Portfolio 350
16.8.4. Recent Developments 350
16.9. Sanofi S.A. 351
16.9.1. Company Overview 351
16.9.2. Sanofi S.A.; Company Revenue Analysis 351
16.9.3. Product Portfolio 352
16.9.4. Recent Developments 352
16.10. Astrazeneca 353
16.10.1. Company Overview 353
16.10.2. Astrazeneca; Revenue Analysis 353
16.10.3. Product Portfolio 354
16.10.4. Recent Developments 354
17. Related Reports 355